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p63 mutations have been associated with EEC syndrome (ectrodactyly, ectodermal dysplasia, and cleft lip/palate),
as well as with nonsyndromic split hand–split foot malformation (SHFM). We performed p63 mutation analysis
in a sample of 43 individuals and families affected with EEC syndrome, in 35 individuals affected with SHFM,
and in three families with the EEC-like condition limb-mammary syndrome (LMS), which is characterized by
ectrodactyly, cleft palate, and mammary-gland abnormalities. The results differed for these three conditions. p63
gene mutations were detected in almost all (40/43) individuals affected with EEC syndrome. Apart from a frameshift
mutation in exon 13, all other EEC mutations were missense, predominantly involving codons 204, 227, 279, 280,
and 304. In contrast, p63 mutations were detected in only a small proportion (4/35) of patients with isolated
SHFM. p63 mutations in SHFM included three novel mutations: a missense mutation (K193E), a nonsense mutation
(Q634X), and a mutation in the 3′ splice site for exon 5. The fourth SHFM mutation (R280H) in this series was
also found in a patient with classical EEC syndrome, suggesting partial overlap between the EEC and SHFM
mutational spectra. The original family with LMS (van Bokhoven et al. 1999) had no detectable p63 mutation,
although it clearly localizes to the p63 locus in 3q27. In two other small kindreds affected with LMS, frameshift
mutations were detected in exons 13 and 14, respectively. The combined data show that p63 is the major gene for
EEC syndrome, and that it makes a modest contribution to SHFM. There appears to be a genotype-phenotype
correlation, in that there is a specific pattern of missense mutations in EEC syndrome that are not generally found
in SHFM or LMS.
Introduction
The central reduction defect of the hands and feet known
as ectrodactyly, split hand–split foot malformation
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(SHFM) or lobster-claw, occurs in ∼1/18,000 newborns
(Czeizel et al. 1993; Evans et al. 1994). On the basis of
linkage studies and the analysis of chromosomal ab-
normalities, three loci have been identified in humans:
SHFM1 on 7q21.3-q22.1 (MIM 183600; Scherer et al.
1994; Crackower et al. 1996), SHFM2 on Xq26 (MIM
313350; Faiyaz ul Haque et al. 1993), and SHFM3 on
10q24-q25 (MIM 600095; Nunes et al. 1995; Raas-
Rothschild et al. 1996). In almost 40% of the cases,
ectrodactyly is associated with other anomalies (Czeizel
et al. 1993; Evans et al. 1994). A well-known example
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Table 1
Oligonucleotides and PCR Conditions for p63 Mutation Analysis
EXON
PRIMER SEQUENCES
SIZE OF
PCR
PRODUCT
(bp)
CONDITIONS
Forward Reverse
Annealing
Temperature
(C)
MgCl2
Concentration
1 TC CCG GCT TTA TAT CTA TAT ATA C GAC ACA TTC ATA ATA CAC AAG GCA C 211 59 2.0
2 TCC ACT TGG GTT TTC ATG ATA GAG GTA AGC AAT ATT TTG ACC ACC CAC 300 58 2.5
3 GCT TGT TGT TAA CAA CAG CAT G GAA AAG ACA GGT TTA ACA GAG C 281 59 2.5
3′ CAT ATT GTA AGG GTC TCA GAG G GAC CGA GAA CCG CAA ATA CG 223 59 1.0
4 GAT CCG TGG CTT CAG CGG AAG CCC ATC CTT GGA CTT GG 354 58 2.5
5 GTT GGT TCT CTC CTT CCT TTC GCC CAC AGA ATC TTG ACC TTC 291 57 3.0
6 CCA CCA ACA TCC TGT TCA TGC GTT CTC TCA AGT CTA CTC AGT CC 267 55 2.5
7 GGG AAG AAC TGA GAA GGA ACA AC CAG CCA CGA TTT CAC TTT GCC 253 55 2.5
8 GTA GAT CTT CAG GGG ACT TTC CCA ACA TCA GGA GAA GGA TTC 260 54 2.5
9 GCT TTA GAA GTG TTC CCA GG ACA CCT CCT TTC CCA TTG TC 237 55 2.5
10 TGA GGA TTG ACC ACA CTT CTA AC CAT CAA TCA CCC TAT TGC TGA TC 287 61 2.0
11 TGA NCA TCA TTT CCA TGT TTG TC TCA CAG AGT CTT GTC CTA AGC 254 57 3.0
12 GGA CTA TAA CAG TAT CCG CCC CAA GAT GGA CCA CTG GGA TG 294 60 2.0
13 CTT ATC TCG CCA ATG CAG TTG G AAC TAC AAG GCG GTT GTC ATC AG 240 55 2.5
14 GGG AAT GAT AGG ATG CTG TGG AAG ATT AAG CAG GAG TGC TT 449 54 2.0
15 GAT GAA GTC CTA GGC CTT C GGA AAT ACA ACA CAC ACA CT 205 55 1.0
is EEC syndrome, which comprises ectrodactyly, ecto-
dermal dysplasia, and cleft lip with or without cleft pal-
ate (MIM 129900 and 602077). EEC syndrome has an
autosomal dominant mode of inheritance with highly
variable expression and reduced penetrance. Ectodermal
dysplasia in EEC syndrome affects the skin, hair, nails,
sweat glands, and teeth (Rodini and Richieri-Costa
1990; Roelfsema and Cobben 1996). Other symptoms
are lacrimal-duct abnormalities, urogenital problems,
conductive hearing loss, facial dysmorphism, chronic/
recurrent respiratory infections, and developmental de-
lay (Gorlin et al. 1990). We recently mapped the genet-
ic defect in EEC syndrome and in an EEC-like condi-
tion called “limb-mammary syndrome” (LMS; MIM
603543) to chromosome 3q27 (Celli et al. 1999; van
Bokhoven et al. 1999). The differentiation of LMS and
EEC syndrome is based on three findings. (1) Mammary-
gland hypoplasia and nipple hypoplasia are consistent
features in LMS and are observed occasionally in EEC
syndrome. (2) Patients with LMS have no hair and skin
defects. (3) Patients with EEC syndrome have cleft lip
with or without cleft palate (CLP), whereas patients with
LMS have cleft palate only (CP). The distinction between
CLP and CP is most relevant, because the affected struc-
tures—the primary palate and the secondary palate,
respectively—develop independently of each other (Fer-
guson 1988; Murray 1995). The p63 gene mapped to
the critical LMS/EEC region on 3q27 (Osada et al. 1998;
Senoo et al. 1998; Trink et al. 1998; Yang et al. 1998).
Subsequent analysis of the p63 gene revealed hetero-
zygous mutations in nine unrelated patients with EEC
syndrome (Celli et al. 1999). Human phenotypes caused
by mutations in the p63 gene are inherited in an auto-
somal dominant pattern. These human phenotypes re-
semble that of p63-knockout mice (Mills et al. 1999;
Yang et al. 1999). More recently, different missense mu-
tations were described in two large families with SHFM
(Ianakiev et al. 2000). We investigated the p63 gene for
mutations in a large group of patients with EEC syn-
drome, in three individuals and families with the EEC-
like LMS, and in 35 patients with SHFM.
Methods
Patients
Patients were enrolled, with informed consent,
through clinical genetic centers in the Netherlands, Bel-
gium, the United States, Italy, Israel, Turkey, Austria,
Germany, and the United Kingdom. The study was ap-
proved by the Nijmegen University Hospital Committee
for Research on Human Subjects. All EEC families and
isolated patients had at least two of the three main fea-
tures of the syndrome. These features are (1) an ecto-
dermal dysplasia affecting the skin, hair, nails, teeth,
sweat glands, lacrimal ducts, or mammary glands; (2)
hand or foot abnormalities consistent with the split
hand–split foot spectrum; and (3) cleft lip with or with-
out cleft palate.
LMS fulfills the EEC criteria. However, the phenotype
is significantly different from classical EEC syndrome,
since the clefting is of the palate alone, the hair and skin
are excluded from the ectodermal involvement, and
there is consistent mammary-gland and nipple aplasia
or hypoplasia (van Bokhoven et al. 1999).
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p63 Mutation Analysis
Intron-specific primers were designed that are suitable
for amplification of exons 1–15 and exon 3′ of the p63
gene (table 1). PCR reactions were carried out in a 25-
ml volume containing 100 ng genomic DNA, 20 mM
Tris-HCl (pH 8.4), 50 mM KCl, varying concentrations
of MgCl2 (see table 1), 0.2 mM dNTPs, 100 ng of each
primer and 1 unit Taq polymerase (Gibco-BRL), using
the following parameters: 1 min at 94C, 2 min at an-
nealing temperature, and 1 min at 72C for 35 cycles
(see table 1 for specific annealing temperatures). PCR
products were fractionated by electrophoresis in 2%
agarose gels and visualized by staining with ethidium
bromide. DNA fragments were excised from the gel and
were purified with the Qiaquick gel extraction protocol
(Qiagen). Sequencing of these fragments was done with
the BigDye Terminator chemistry (PE Applied Biosys-
tems) and the use of exon-specific primers. Electropho-
resis and analysis were performed on an ABI Prism 3700
(PE Applied Biosystems).
In familial cases, it was verified that the mutation seg-
regated with the phenotype. For sporadic cases, the ab-
sence of mutation was tested in both parents, if they
were available for these studies. All of the sequence al-
terations were checked in50 control individuals, either
by allele-specific oligonucleotide (ASO) hybridization,
by restriction enzyme digestion of PCR products from
the relevant exons, or by direct sequencing. ASO hy-
bridization and washing were performed with primers
5′-ATGAAC(C/G)ACCGTCCAATT-3′ for R279H, 5′-
GTGGTGAAG(C/T)GGTGCCCCAC-3′ for R204W, 5′-
GTGGTGAAGC(G/A)GTGCCCCAC-3′ for R204Q, as
described by Shuber et al. (1993). The position of mu-
tations corresponds to the coding sequence for the orig-
inal published TA-p63a isotype (GenBank accession
AF075430) (Yang et al. 1998), which does not include
the 39 additional codons for the amino-terminal end that
were reported later by Hagiwara et al. (1999) (GenBank
accession AF091627).
Exon Trapping
The effect of the 3′ splice-site mutation in intron 4
was investigated by exon trapping. For this, exon 5 and
its flanking intron sequences were amplified with primers
ET5F (5′-CTG GAG CTC GCC AGT CAA TAT CTC
CTG TT-3′) and ET5R (5′-TGG GAT CCC TGA TCT
GCC ATC GGA GTG-3′), using genomic DNA from the
SHFM patient with the intron 4 splice-site mutation as
template. Amplification conditions were as described
above. PCR products were digested with SstI and
BamHI, for which unique recognitions were contained
in the amplification primers. The resulting 187-bp frag-
ments were cloned in the SstI and BamHI sites of pSPL3
(Church et al. 1994). The integrity of the resulting
clones, containing either the wild-type sequence or the
splice site mutation, was checked by sequence analysis.
Cos-1 cells were transfected with either wild-type or mu-
tant construct, and exon trapping was performed ac-
cording to the manufacturer’s conditions (Life Technol-
ogies). The resulting RT-PCR products were analyzed by
means of electrophoresis on a 1.5% agarose gel. Bands
of 364 bp were excised from the gel and were sequenced,
by use of primers SD2 and SA4, for the pSPL3-encoded
exons (Life Technologies).
FISH Analysis
Metaphase spreads from lymphocytes were prepared
using standard procedures, and FISH was performed as
described elsewhere (Suijkerbuijk et al. 1991). DNA
from YAC clone 889A7 (Celli et al. 1999) was labeled
with digoxigenin (Boehringer) and was immunocyto-
chemically detected. Chromosomes were stained with
4′,6-diamidino-2-phenylindole-dihydrochloride (DAPI).
Centromere 3–specific staining was obtained with a Cy3-
labeled alphoid DNA probe (Waye and Willard 1989).
Results
Mutation Analysis
Comprehensive analysis of the coding region of the
p63 gene included exons 1–15 and the flanking intronic
sequences and used the primers listed in table 1. A total
of 46 mutations were detected in individuals with EEC,
LMS, and SHFM (table 2 and fig. 1), including 9 mu-
tations that have been reported elsewhere (Celli et al.
1999). Evidence that the mutations are indeed causative
for these disorders was provided by several observations.
(1) The changes are de novo in 27 of the 46 cases. For
16 of the 23 different types of mutations, the occurrence
of de novo mutations could be demonstrated. (2) For
10 of the 13 familial cases, additional patients and
healthy relatives were available for genetic testing (table
2). Cosegregation of the mutation and phenotype was
observed in all 10 of these families. (3) All missense
mutations are predicted to affect the DNA-binding
capacity of p63 (Celli et al. 1999; Ianakiev et al. 2000;
G. Vriend, P. H. G. Duijf, and H. van Bokhoven, un-
published data). Accordingly, impaired transactivation
activity and altered regulation of transactivation were
observed for the two mutations that have been tested
(C306 R and R304W; Celli et al. 1999 and results not
shown). (4) None of the mutations were identified in a
cohort of 50 control individuals.
Mutations were detected in 40 unrelated patients and
families, of a total of 43 families affected with EEC. This
series includes the 9 mutations reported elsewhere (Celli
et al. 1999) and 31 not reported elsewhere (table 2 and
fig. 1). Missense mutations of codon R204 were present
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Figure 1 Distribution of p63 gene mutations in EEC syndrome, SHFM, and LMS. Except for one frameshift mutation in exon 13, all
mutations in EEC syndrome are amino acid substitutions in the DNA-binding domain that are predicted to abrogate interaction with the DNA
and, hence, reduce transactivation activity. LMS mutations are frameshifts in exons 13 and 14. The EEC syndrome patient with the exon 13
frameshift mutation also has clinical characteristics of LMS. The mutations identified in patients with SHFM are distributed along the gene.
Substitution of arginine 280 may give rise to either classical EEC syndrome or SHFM.
in 10 families, of which 6 were R204W and 4 were
R204Q. Mutations of codon 279 occurred in eight fam-
ilies, R279H in four families, R279C in three families,
and R279Q in one family. The R227Q mutation was
detected in three unrelated families, including two fam-
ilies that have been reported previously (O’Quinn et al.
1998). Another frequent site of mutations is amino acid
304, which had mutation R304Q in five families and
mutation R304W in two. Three families had R280C.
Among families affected with EEC, single families had
S272N, C306R, C308S, P309S, and D312H. Frameshift
mutations in exons 13 and 14 were present in three
families. An insertion of a single nucleotide (1572insA)
in exon 13 was present in a patient EEC with reported
elsewhere (Celli et al. 1999). A 2-bp deletion (1693–
1694DelTT) in exon 13 was present in one family with
LMS, and a 2-bp deletion (1860–1861DelAA) in exon
14 was present in another family with LMS. No mu-
tation was detected in the original family with LMS (van
Bokhoven et al. 1999) after sequencing of the entire
coding region of the p63 gene. Mutations were detected
in 4 of 35 families with SHFM. p63 mutations in SHFM
included a missense mutation (K193E) in a father and
his son, a de novo nonsense mutation (Q634X), and a
de novo mutation in the 3′ splice site for exon 5. The
fourth SHFM mutation (R280H) in this series was iden-
tical to a mutation observed in a patient with classical
EEC syndrome, suggesting partial overlap between the
EEC and SHFM mutational spectra. This patient with
SHFM is a sporadic case, whose parents were unavail-
able for genetic testing. Thus, three of the four SHFM
mutations were clearly different from those found in
EEC syndrome (fig. 1).
3′ Splice-Site Mutation in Intron 4 Gives Rise
to In-Frame Alternative-Splicing Products
The IVS4-2ArC mutation in a patient with SHFM
abrogates the strictly conserved adenosine of the accep-
tor splice site. No patient material was available for
direct examination, by RT-PCR, of the effect of this
mutation. As an alternative strategy, an exon-trapping
experiment was performed to investigate the effect of
this mutation on splicing. Transfection of COS-1 cells
with an exon-trapping construct containing the wild-
type sequences of exon 5 and flanking intron sequences
yielded transcripts that were properly spliced at the re-
ported splice-site junctions (fig. 2). In contrast, the same
construct containing the IVS4-2ArC mutation yielded
transcripts that were the result of splicing at position
3 of the normal boundary between intron 4 and exon
5 (fig. 2). This result indicates that the IVS4-2ArC mu-
tation gives rise to an insertion of a CCG codon for a
proline residue at amino acid position 154.
Lack of EEC-Like Features in a Patient with a
Heterozygous Deletion of the p63 Gene
Metaphase chromosomes from a patient carrying a
deletion 3q27-3qter were used for FISH analysis to de-
termine whether the p63 gene was contained in the de-
letion. This patient had multiple congenital anomalies,
including bilateral anophthalmia, congenital heart dis-
ease, and abnormal genitalia, but no features reminiscent
of EEC syndrome (Chitayat et al. 1996). DNA from a
YAC clone 889A7 containing the p63 gene was labeled
and was used for the FISH analysis. All cells that could
be scored showed a fluorescent signal only on the normal
van Bokhoven et al.: p63 Mutations in EEC and SHFM 487
Figure 3 Partial karyotype of a patient with a terminal deletion
of the long arm of chromosome 3 [46,XX,del(3)(q27rqter)]. The pa-
tient has multiple congenital abnormalities, but none of the symptoms
is typical of EEC syndrome (Chitayat et al. 1996). Shown is the staining
of a typical cell after FISH. Only the nondeleted chromosome 3 shows
staining of the YAC containing the p63 gene (closed arrow), whereas
both chromosomes 3 show centromeric staining (open arrow).
Figure 2 Predicted effect of the splice-site mutation in the p63 gene. a, Predicted consequence of the 3′ splice-site mutation. The strictly
conserved adenosine of the acceptor splice site has been substituted by a cytosine. An excellent alternative 3′ splice site is located just three
nucleotides in front of the original one. Splicing at this alternative site results in an insertion of one proline residue for the mutant allele. The
adherence to the 3′ splice-site consensus sequence was calculated according to the method of Shapiro and Senapathy (1987). b, The IVS4-2ArC
mutation gives rise to alternative splicing. Sequence analysis of the RT-PCR product obtained in an exon-trapping assay in which COS-1 cells
were transfected with either a wild-type construct (top panel) or a construct containing the splice-site mutation (bottom panel). The reverse
complement sequence is shown. The mutation results in incorporation of an additional proline codon in the transcript.
chromosome 3 and not on the deletion chromosome 3
(fig. 3).
Discussion
This study shows that 40 of 43 patients with EEC syn-
drome have heterozygous missense mutations of the p63
gene (table 2). From our studies a striking pattern is
emerging in which mutations affecting amino acid res-
idues 204, 227, 279, 280, and 304 are responsible for
the large majority of all p63 gene mutations in EEC
syndrome (table 2). Several explanations are possible for
this highly specific distribution of p63 gene mutations.
First, the mutations may occur at nucleotides which
are highly mutable. Support for this is the high fre-
quency (60%) of de novo mutations in EEC syndrome
(table 3). This possibility is further supported by the
fact that EEC mutation hotspots in the p63 gene cor-
respond exactly with the sites of frequently mutated
amino acids in the homologous p53 gene in various
cancers (Celli et al. 1999; Hernandez-Boussard et al.
1999). Conversely, of the five most frequently mutated
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Table 3
p63 Mutations in Patients with EEC Syndrome, LMS, and SHFM
Amino Acid
No. of
Families Exon CpG Islet Transition
De Novo
Mutationsa Disorder
IVS4-2ArC 1 5b  ArC 0 SHFM
K193E 1 5  ArG  SHFM
R204W 6 6  CrT 5 , 1  EECc
R204Q 4 6  GrA 2 , 2  EECc
R227Q 3 6  GrA  EEC
C269Y 1 7  GrA ? EEC
S272N 1 7  GrA  EECc
R279H 4 7  GrA 3 , 1  EEC
R279C 3 7  CrT 2 , 1 ? EEC
R279Q 1 7  GCrAA  EEC
R280C 3 7  CrT 1 , 2  EECd
R280S 1 7  CrA ? EEC
R280H 2 7  GrA 1, 1 ? EEC/SHFM
R304W 2 8  CrT 1 , 1 ? EECc
R304Q 5 8  GrA 4 , 1 ? EEC
C306R 1 8  TrC  EECc
C308S 1 8  TrA  EEC
P309S 1 8  CrT  EEC
D312H 1 8  GrC  EEC
1689InsA 1 13    EECc
1693-1694DelTT 1 13   ? LMS
1860-1861DelAA 1 14    LMS
Q634X 1 14  CrT  SHFM
Overall 46 34 32/34e C:G to T:A 27 , 10 , 7 ?
a The question mark (?) indicates that there was insufficient clinical and/or molecular data for the parents.
A plus sign () indicates a confirmed de novo mutation, and a minus sign () indicates a familial mutation.
b Intron mutation detected on analysis of exon 5.
c This mutation has been reported elsewhere by Celli et al. (1999).
d This mutation has also been reported in a family with SHFM (Ianakiev et al. 2000).
e Indicated is the number of C:G to T:A transitions at CpG sites. At non-CpG sites, 4 of 12 mutations are
C:G to T:A transitions.
amino acids of p53 in human tumor material, only one
does not have a homologous mutation of p63 in EEC
syndrome. Strikingly, 34 of the 46 mutations in this
series involve CpG sites. All of these 34 CpG mutations
are at frequently mutated sites, whereas each of the non-
CpG mutations is unique in our series (table 3). Another
significant finding is that 32 of 34 CpG site mutations
are C:G to T:A transitions—19 on the transcribed strand
and 13 on the nontranscribed strand. The high muta-
bility of 5-methylcytosine at CpG sites (Coulondre et
al. 1978; Brown and Jiricny 1987; Rideout et al. 1990)
is a likely explanation for the high proportion of the
recurrent mutations in EEC syndrome. Somatic p53
mutations in human cancers are also frequently C:G to
T:A transitions at CpG dinucleotides (Hernandez-Bous-
sard et al. 1999), and there is experimental evidence
suggesting that these sites are foci for DNA damage
(Denissenko et al. 1996), as well as foci for damage that
is poorly repaired (Tornaletti and Pfeifer 1994). A sim-
ilar mechanism may apply to the p63 mutation hot-
spots identified in EEC syndrome.
A second possibility is that the mutation spectrum in
EEC syndrome reflects a specific pathogenetic mecha-
nism. This possibility is supported by the finding that
a number of different missense mutations occurred at
amino acids 204, 279, 280, and 304. There are several
precedents in the literature for this type of selectivity.
Most notably, almost all FGFR3 gene mutations in
achondroplasia occur at two amino acids, G380R and
G375C (Bellus et al. 1995). This bias for specific mu-
tations reflects a gain of function-mechanism (Li et al.
1997). Gain of function properties have previously been
proposed for several missense mutations in the p53
gene, in codons that are analogous to those mutated in
EEC syndrome (Dittmer et al. 1993; Gualberto et al.
1998).
Third, the phenotypes of patients with other muta-
tions of the p63 gene may differ from those found in
classical EEC syndrome. Such cases would not be ex-
amined in our study, which used restrictive diagnostic
criteria. A number of syndromes share similarity with
EEC syndrome (Rodini and Richieri-Costa 1990),
notably ankyloblepharon-ectodermal defects–cleft lip/
palate (AEC) syndrome (Hay and Wells 1976), acro-
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dermato-ungual-lacrimal-tooth (ADULT) syndrome
(Propping and Zerres 1993), and lacrimo-auriculo-
dento-digital (LADD) syndrome (Hollister et al. 1973).
In fact, three of four mutations found in SHFM were
clearly different from those found in the group affected
with EEC syndrome. Moreover, we have recently shown
that missense mutations in the SAM domain (exon 13)
of the p63 gene are specifically associated with AEC
syndrome (McGrath et al. 2001).
It should be noted that the three explanations offered
here are not mutually exclusive. It is quite possible that
EEC syndrome is, in fact, caused by specific amino acid
changes that result in a change of function and also
preferentially involve certain nucleotides with high
mutability.
At the very least, a haploinsufficiency model can be
discarded, since patients with constitutive deletions of
3q27 have none of the defining features of EEC syn-
drome (fig 3.; Chitayat et al. 1996). Also, mice carrying
a heterozygous deletion of the p63 gene do not have
any apparent defects (Mills et al. 1999; Yang et al.
1999). In vitro expression studies of wild-type and mu-
tant p63 gene constructs demonstrate complex effects
on transactivation and repressor functions of the six
different p63 isotypes (Celli et al. 1999; McGrath et al.
2001). Such studies also argue in favor of a dominant
negative effect, a change of function, or even a partial
gain of function of p63 in EEC syndrome.
The three frameshift mutations were all in exons 13
and 14. One of these was a single-nucleotide insertion
(1572insA), which we reported previously (Celli et al.
1999). This concerns a single patient with a phenotype
most consistent with a diagnosis of EEC syndrome, al-
though other features suggested LMS. The patient has
bilateral typical SHFM, hypodontia, unilateral cleft lip
and palate, lacrimal duct abnormalities, and dystrophic
nails. In contrast with most typical EEC patients, she
has normal skin. Another pertinent finding in this pa-
tient is bilateral aplasia of the mammary glands, which
is more typical of LMS (van Bokhoven et al. 1999). The
other frameshift mutations both occurred in patients
with a phenotype that is more characteristic of LMS.
The first typical LMS case has a 2-bp deletion
(1576–1577delTT) in exon 13. This patient has bilat-
eral SHFM, isolated cleft palate, and normal hair, skin,
and teeth, but absent nipples. The other LMS patient
has a 2-bp deletion in exon 14. This patient also has a
typical LMS phenotype with bilateral SHFM, absence
of the lacrimal punctae, submucous cleft palate, bilat-
eral ear pits, and somewhat dry skin on the trunk. The
nipples are absent. The anus was anteriorly placed. All
three frameshift mutations affect only the p63a iso-
types, which have dominant-negative effects on trans-
activation, whereas the b and g isotypes may be nor-
mally produced. The two frameshift mutations in exon
13 are predicted to yield similar protein products with
premature truncations in the SAM domain, whereas the
frameshift in exon 14 does not affect the SAM domain
(figs. 1). The combined clinical data on the three frame-
shift mutations suggest that they represent a specific
group characterized by absence of the nipples and mam-
mary glands and relatively mild ectodermal involve-
ment. Such findings are unusual in EEC but are very
typical in LMS (van Bokhoven et al. 1999). One of these
patients, however, has been classified as having EEC
syndrome, because the patient has CLP rather than CP.
No mutation was detected on sequencing of the entire
coding region (exons 1–15) of the p63 gene in the large
Dutch family with LMS (van Bokhoven et al. 1999).
There is very clear evidence for linkage of LMS with
the p63 gene region on 3q27, with a maximum LOD
score of 112 (van Bokhoven et al. 1999). It would seem
likely that, in this family, LMS results from a mutation
that is outside the p63 coding region, either in an intron
or in a regulatory region of the gene. Interestingly, of
the three patients without a mutation who fulfilled our
EEC criteria, two had cleft palate without cleft lip, and
both of these had mammary gland hypoplasia. Except
for the involvement of skin defects, these two cases are
typical for LMS.
In this series, p63 gene mutations were detected in
only a small proportion (4/35) of patients and families
with isolated SHFM. We found a novel missense mu-
tation (K193E) in a patient with SHFM. The father of
this patient has the same mutation but shows only
minor foot anomalies: bilateral syndactyly I-II, bilateral
small cleft II-III, and left cutaneous syndactyly III-IV
(Witters et al., in press). This mutation has not been
reported elsewhere, in either EEC or SHFM. However,
a mutation of the adjoining amino acid (K194E) has
been reported elsewhere, also in a patient with SHFM
(Ianakiev et al. 2000). The K194E mutation also gives
rise to variable effects, and even several cases of non-
penetrance were reported (Ianakiev et al. 2000). Two
other mutations in SHFM patients are different from
those found in EEC. The only nonsense mutation in this
series (Q634X) occurred in a patient with SHFM, as
did a mutation in the 3′ splice site in intron 4. This
splice-site mutation is likely to give rise to alternative
splicing rather than to skipping of exon 5, because the
latter is likely to be a loss-of-function event. Three nu-
cleotides in front of the normal 3′ splice site is a potential
splice-acceptor site (fig. 2). Use of this alternative site
would lead to insertion of a proline amino acid at po-
sition 233 in the DNA-binding domain. Indeed, this
alternative splicing route was used for this mutation in
an exon-trapping assay (fig. 2). Although unlikely, we
cannot formally exclude the possibility that this mu-
tation generates a haploinsufficiency in the patient. The
fourth SHFM mutation (R280H) in our study was also
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identified in a classical case of EEC syndrome. The
mother of this patient with SHFM is a nonmanifesting
carrier of the R280H mutation. A mutation at the same
codon, R280C, has been described elsewhere in a single
large South African family with SHFM (Ianakiev et al.
2000). Conversely, we detected the R280C mutation in
three unrelated cases with classical EEC syndrome, in-
cluding nail dysplasia, dry skin, orofacial clefting, and
hypodontia. At least seven members of the South Af-
rican family with SHFM received an in-depth clinical
investigation, and no evidence for ectodermal involve-
ment or clefting was found (Ianakiev et al. 2000). These
data strongly suggest that codon 280 mutations can
cause either EEC or SHFM. A similar situation has pre-
viously been described for the FGFR2 gene, in which
some mutations are specifically associated with either
Crouzon syndrome or Pfeiffer syndrome, but others,
like the Cys342Arg mutation, were found in both these
conditions or in Jackson-Weiss syndrome (Rutland et
al. 1995; Tartaglia et al. 1997).
In conclusion, we show that most, if not all, patients
with EEC syndrome have p63 gene mutations. Geno-
type-phenotype correlations exist in that the specific
mutations in EEC syndrome are not generally found in
SHFM or LMS. With the exception of a frameshift mu-
tation in exon 13, these mutations change specific amino
acids in the DNA-binding domain (exons 5–8 of the
gene). LMS patients are likely to have frameshift mu-
tations near the 3′ end of the gene. The mutation spec-
trum for SHFM is different and includes nonsense and
splice-site mutations, as well as missense mutations not
usually found in EEC. The proportion of SHFM patients
with p63 gene mutations is low, and the majority of
SHFM cases are likely to be due to mutations in other
genes. The high phenotypic variability that is observed
for specific mutations—in particular, the finding that
mutations at codon 280 can cause either EEC or SHFM
in different families—suggests the importance of mod-
ifying factors, the nature of which remains to be
determined.
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